CSIMarket
 


Frequency Therapeutics Inc   (FREQ)
Other Ticker:  
 

Frequency Therapeutics Inc 's Working Capital Ratio

FREQ's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth




FREQ Working Capital Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities Change 90.78 % 85.59 % -35.66 % -57.09 % -68.15 %
Y / Y Current Assets Change -32.63 % -34.2 % -40.05 % -40.13 % -34.06 %
Working Capital Ratio MRQ 5.05 6.77 9.85 11.79 14.3
Overall Ranking # # # # #
Seq. Current Liabilities Change 19.34 % 37.7 % 6.5 % 9 % 16.1 %
Seq. Current Assets Change -10.96 % -5.43 % -10.99 % -10.11 % -13.03 %



Working Capital Ratio third quarter 2022 Comment
Due to increase in Current Liabilities in the third quarter 2022, Working Capital Ratio fell to 5.05 above Frequency Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry Frequency Therapeutics Inc booked the highest Working Capital Ratio than Frequency Therapeutics Inc in the third quarter 2022. While total ranking remained unchanged compare to previous quarter at no. .

Explain Working Capital Ratio
Where is FREQ most successful ?
Working Capital Ratio FREQ on the trailing twelve month basis
Working Capital Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Working Capital Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Frequency Therapeutics Inc 's Current Liabilities $ 20 Millions Visit FREQ's Balance sheet
Frequency Therapeutics Inc 's Current Assets $ 101 Millions Visit FREQ's Balance sheet
Source of FREQ's Sales Visit FREQ's Sales by Geography


Cumulative Frequency Therapeutics Inc 's Working Capital Ratio

FREQ's Working Capital Ratio for the trailling 12 Months

FREQ Working Capital Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities TTM Growth 90.78 % 85.59 % -35.66 % -57.09 % -68.15 %
Y / Y Current Assets TTM Growth -32.63 % -34.2 % -40.05 % -40.13 % -34.06 %
Working Capital Ratio TTM 7.77 10.19 13.38 13.18 11.49
Total Ranking TTM # 324 # 523 # 77 # 266 # 377
Seq. Current Liabilities TTM Growth 19.34 % 37.7 % 6.5 % 9 % 16.1 %
Seq. Current Assets TTM Growth -10.96 % -5.43 % -10.99 % -10.11 % -13.03 %


TTM Working Capital Ratio Comment
On the trailing twelve months basis Due to increase in Current Liabilities in the III. Quarter to $20.00 millions, average cumulative Working Capital Ratio decreased to 7.77 below the Frequency Therapeutics Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 127 other companies have achieved higher Working Capital Ratio than Frequency Therapeutics Inc . While overall ranking remained unchanged compare to previous quarter at no. 324.

Explain Working Capital Ratio
Where is FREQ most successful ?
Working Capital Ratio FREQ on the trailing twelve month basis

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 128
Healthcare Sector # 211
Within the Market # 324


TTM Working Capital Ratio Statistics
High Average Low
13.38 8.27 3.7
(Mar 31 2022)   (Mar 31 2020)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2022 MRQ Current AssetsSep 30 2022 MRQ Current Liabilities
Liquidia Corporation  13.81 $ 103.058  Millions$ 7.460  Millions
Annexon Inc   13.59 $ 274.777  Millions$ 20.220  Millions
Larimar Therapeutics Inc   13.50 $ 127.127  Millions$ 9.420  Millions
Aclaris Therapeutics Inc   13.49 $ 256.573  Millions$ 19.023  Millions
Xenetic Biosciences Inc   13.48 $ 14.167  Millions$ 1.051  Millions
Iveric Bio Inc   13.40 $ 329.478  Millions$ 24.588  Millions
Arcutis Biotherapeutics Inc   13.39 $ 496.719  Millions$ 37.102  Millions
Erasca Inc   13.21 $ 365.751  Millions$ 27.679  Millions
Kronos Bio Inc   13.16 $ 264.630  Millions$ 20.105  Millions
Pepgen Inc   13.16 $ 204.248  Millions$ 15.519  Millions
Graybug Vision Inc   13.03 $ 45.071  Millions$ 3.460  Millions
Lyell Immunopharma Inc   12.88 $ 659.745  Millions$ 51.217  Millions
Reneo Pharmaceuticals Inc   12.80 $ 120.998  Millions$ 9.450  Millions
Rallybio Corporation  12.80 $ 142.429  Millions$ 11.130  Millions
Milestone Pharmaceuticals Inc   12.71 $ 82.921  Millions$ 6.522  Millions
Cogent Biosciences Inc   12.59 $ 296.417  Millions$ 23.551  Millions
Hcw Biologics Inc   12.52 $ 28.708  Millions$ 2.293  Millions
Centessa Pharmaceuticals Plc  12.49 $ 476.990  Millions$ 38.191  Millions
Allakos Inc   12.30 $ 339.202  Millions$ 27.588  Millions
Cymabay Therapeutics Inc   12.20 $ 155.124  Millions$ 12.711  Millions
Metacrine Inc   12.15 $ 55.037  Millions$ 4.529  Millions
Capricor Therapeutics inc   12.07 $ 47.505  Millions$ 3.937  Millions
Corcept Therapeutics Inc  12.04 $ 452.402  Millions$ 37.590  Millions
Ideaya Biosciences Inc   12.02 $ 393.437  Millions$ 32.727  Millions
Viking Therapeutics Inc   12.00 $ 165.146  Millions$ 13.762  Millions
United Therapeutics Corporation  11.95 $ 3,056.400  Millions$ 255.800  Millions
Cormedix Inc   11.79 $ 59.664  Millions$ 5.062  Millions
Medicinova Inc   11.74 $ 53.149  Millions$ 4.528  Millions
Ventyx Biosciences Inc   11.73 $ 418.390  Millions$ 35.661  Millions
Diffusion Pharmaceuticals Inc   11.59 $ 26.323  Millions$ 2.271  Millions

Date modified: 2022-11-10T15:28:51+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

XGN's Profile

Stock Price

XGN's Financials

Business Description

Fundamentals

Charts & Quotes

XGN's News

Suppliers

XGN's Competitors

Customers & Markets

Economic Indicators

XGN's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071